<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190901044666N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-18</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of fractional CO2 laser in combination with 5-fluorouracil cream compared to PDL laser in the treatment of hypertrophic and keloidal scars</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the efficacy of fractional CO2 laser in combination with 5-fluorouracil cream compared to PDL laser in the treatment of hypertrophic and keloidal scars: A randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67481</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the simple randomization method, the patients who refer to the laser clinic of Hazrat Fatemeh Hospital are placed in 2 groups in such a way that one envelope is randomly selected for each patient from the number of 24 sealed envelopes. Inside each envelope is the letter A or B. Group A patients will be treated with PDL laser and group B patients will be treated with fractional CO2 laser in combination with 5FU cream, Blinding description: Due to the clear difference between the mentioned therapeutic interventions, it was not possible to blind the therapist and the patients, and as a result, the study will be conducted in a one-sided blind manner. In other words, the evaluation of the results of the studies will be done by an evaluator who is blind to the type of intervention (a dermatologist who does not know which treatment group the patient is in) and based on the images taken of the lesions in each session. Also, data analysis will be done by a blinded statistician.</study_design>
      <phase>3</phase>
      <hc_freetext>Hypertrophic scar.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Fractional CO2 laser treatment in combination with 5FU cream: Before the intervention, gentle cleaning of the desired lesion will be done using gauze soaked in normal saline. Then 60 minutes before the laser treatment, local anesthetic cream containing 2.5% lidocaine and 2.5% prilocaine (Xyla-P, Tehran Chemie, Tehran, Iran) will be applied on the lesion. At the end of 60 minutes, the local anesthetic cream will be removed using alcohol cotton. Then fractional CO2 laser will be applied using Deka SmartXide DOT (Deka, Florence, Italy) laser device (with power 14, stack 2, space 600 and dwell time 600) in each lesion area of 5x5 cm2. Immediately after laser treatment, five percent 5FU cream is used in the lasered area and this treatment will continue twice a day for 5 days. Intervention 2: Control group: PDL laser treatment:Before the intervention, gentle cleaning of the desired lesion will be done using gauze soaked in normal saline. Then PDL laser using Deka Alexandrite laser device (Synchro VasQ, Deka, Florence, Italy) with spot size of 7 mm, single duration of 0.5 milliseconds and power of 7 J/cm2 with 50 shots per 5x5 lesion area Square centimeters will apply.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Afsaneh Sadeghzadeh bazargan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2421</telephone>
        <email>sadeghzadeh.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Afsaneh Sadeghzadeh bazargan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2421</telephone>
        <email>sadeghzadeh.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years old
Patients with a confirmed diagnosis of erythematous hypertrophic scar in the number of at least 2
The size of the waste should be at least 5x5 cm square or have a length of at least 5 cm
The patient is not pregnant or breastfeeding
During the last two months, the patient has not received any treatment for the lesions, including laser treatment, topical or injectable corticosteroids
The patient has no underlying diseases that lead to scar healing process; such as diabetes or weakened immune system
The patient's cooperation in carrying out therapeutic interventions and referring for all therapeutic sessions</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L91.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypertrophic scar</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Fractional CO2 laser treatment in combination with 5FU cream: Before the intervention, gentle cleaning of the desired lesion will be done using gauze soaked in normal saline. Then 60 minutes before the laser treatment, local anesthetic cream containing 2.5% lidocaine and 2.5% prilocaine (Xyla-P, Tehran Chemie, Tehran, Iran) will be applied on the lesion. At the end of 60 minutes, the local anesthetic cream will be removed using alcohol cotton. Then fractional CO2 laser will be applied using Deka SmartXide DOT (Deka, Florence, Italy) laser device (with power 14, stack 2, space 600 and dwell time 600) in each lesion area of 5x5 cm2. Immediately after laser treatment, five percent 5FU cream is used in the lasered area and this treatment will continue twice a day for 5 days.</i_keyword>
      <i_keyword>Control group: PDL laser treatment:Before the intervention, gentle cleaning of the desired lesion will be done using gauze soaked in normal saline. Then PDL laser using Deka Alexandrite laser device (Synchro VasQ, Deka, Florence, Italy) with spot size of 7 mm, single duration of 0.5 milliseconds and power of 7 J/cm2 with 50 shots per 5x5 lesion area Square centimeters will apply.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Effectiveness of treatment on scar. Timepoint: Scar score measurement at the beginning of the study (before the start of the intervention) and after the end of the third session of the intervention (3 months later). Method of measurement: Vancouver scar scale (VSS) scoring method will be used to check the effectiveness of the treatment. This scale includes examination of 4 characteristics of the lesion, including: vascularity, pigmentation, height and flexibility, which are scored for each characteristic and the sum of all points will be checked in order to evaluate the improvement of the lesion.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-23</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Rasoul Akram Hospital, At the corner of Mansouri St, Niayesh St, Satarkhan St Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
